Novel Antidepressants

Major depressive disorder (MDD) remains one of the most prevalent and disabling psychiatric illnesses worldwide, with substantial limitations in the efficacy and onset of traditional monoaminergic antidepressants. Recent advances in neurobiology have expanded the therapeutic landscape toward novel agents that target alternative systems, including glutamatergic, GABAergic, melatonergic, and neuroinflammatory pathways. This chapter reviews emerging antidepressants with rapid-onset and mechanistically diverse profiles, such as esketamine, brexanolone, zuranolone, psilocybin, trace amine-associated receptor 1 (TAAR1) agonists, and agomelatine. These agents demonstrate faster symptom relief and improved efficacy in treatment-resistant depression (TRD), postpartum depression (PPD), and acute suicidal ideation. Evidence from randomized clinical trials indicates significant and durable antidepressant effects, though issues of cost, accessibility, and long-term safety remain. Mechanistic insights highlight modulation of N-methyl-D-aspartate (NMDA) and GABA_A receptors, enhancement of neuroplasticity via brain-derived neurotrophic factor-mammalian target of rapamycin (BDNF-mTOR) signaling, and regulation of circadian and immune processes. The evolution of these therapies represents a paradigm shift from symptom-based to mechanism-guided treatment, aligning with the emerging principles of precision psychiatry. Future directions emphasize biomarker-guided selection, integration of digital health tools, and the exploration of next-generation targets, including neuroplasticity enhancers, orexin antagonists, and epigenetic modulators.